Off-label uses of the Amplatzer Piccolo Occluder in children with congenital and acquired heart diseases
Year: 2024
Type: article
Study design: Case Report
Abstract: Aim: The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions.Methods: Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023.Results: The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder. All nine patients had successful occlusions without complications.Conclusion: The APO is a versatile device that can be used to treat various small diameter lesions in children besides the PDA for which it is currently approved for.
Source: Future Cardiology
Authors: Ashley Molloy, Neil Tailor, Ronak Naik, Nithya Swaminathan, Mohammed Absi, Anthony Merlocco, Jason Johnson, Shyam Sathanandam
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4402275544